Skip to Content
Merck
  • O-GlcNAcylation of TDP-43 suppresses proteinopathies and promotes TDP-43's mRNA splicing activity.

O-GlcNAcylation of TDP-43 suppresses proteinopathies and promotes TDP-43's mRNA splicing activity.

EMBO reports (2021-04-16)
Meng-Jie Zhao, Xiao Yao, Ping Wei, Chen Zhao, Meng Cheng, Dong Zhang, Wen Xue, Wen-Tian He, Weili Xue, Xinxin Zuo, Lei-Lei Jiang, Zhiyuan Luo, Jiaqi Song, Wen-Jie Shu, Han-Ye Yuan, Yi Liang, Hui Sun, Yan Zhou, Yu Zhou, Ling Zheng, Hong-Yu Hu, Jiwu Wang, Hai-Ning Du
ABSTRACT

Pathological TDP-43 aggregation is characteristic of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP); however, how TDP-43 aggregation and function are regulated remain poorly understood. Here, we show that O-GlcNAc transferase OGT-mediated O-GlcNAcylation of TDP-43 suppresses ALS-associated proteinopathies and promotes TDP-43's splicing function. Biochemical and cell-based assays indicate that OGT's catalytic activity suppresses TDP-43 aggregation and hyperphosphorylation, whereas abolishment of TDP-43 O-GlcNAcylation impairs its RNA splicing activity. We further show that TDP-43 mutations in the O-GlcNAcylation sites improve locomotion defects of larvae and adult flies and extend adult life spans, following TDP-43 overexpression in Drosophila motor neurons. We finally demonstrate that O-GlcNAcylation of TDP-43 promotes proper splicing of many mRNAs, including STMN2, which is required for normal axonal outgrowth and regeneration. Our findings suggest that O-GlcNAcylation might be a target for the treatment of TDP-43-linked pathogenesis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
PUGNAc, ≥95% (HPLC)
Sigma-Aldrich
Anti-c-Myc antibody, Mouse monoclonal, clone 9E10, purified from hybridoma cell culture
Millipore
ANTI-FLAG® antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Anti-O-GlcNAc Antibody, clone CTD110.6, clone CTD110.6, from mouse